Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2007
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:L01XE09
|
| gptkbp:brand |
gptkb:temsirolimus
|
| gptkbp:CASNumber |
gptkb:162635-04-3
|
| gptkbp:chemicalFormula |
C56H87NO16
|
| gptkbp:contraindication |
hypersensitivity to temsirolimus
|
| gptkbp:developedBy |
gptkb:Wyeth_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
17.3 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Torisel
|
| gptkbp:indication |
gptkb:advanced_renal_cell_carcinoma
|
| gptkbp:KEGGID |
D06402
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
mTOR inhibitor
|
| gptkbp:MedlinePlusID |
a607053
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201737
gptkb:DB06287 6918283 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
nausea diarrhea fatigue rash hyperglycemia |
| gptkbp:UNII |
6HG8UB2MUY
|
| gptkbp:usedFor |
renal cell carcinoma
|
| gptkbp:bfsParent |
gptkb:Wyeth
|
| gptkbp:bfsLayer |
5
|